drugset / Trial / NCT05013515
Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of Surufatinib Neoadjuvant Therapy for Locally Advanced Primary Saliary Gland Adenocarcinoma.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2022-09
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |